B
Bull
Bull · 25%TERN
$5.84
Szenariopreis
$52.950
+0.021 (+0.04%)Zum Schluss
Loading chart…
- High
- 52.980
- Open
- 52.970
- VWAP
- 52.96
- Vol
- 6.35M
- Mkt Cap
- 459.85M
- Low
- 52.940
- Amount
- 336.12M
- EV/EBITDA, TTM
- 0.00
Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Its product candidates in pipeline includes TERN-701, TERN-601 and TERN-501. TERN-701 is its oral, potent, allosteric BCR-ABL tyrosine kinase inhibitors (TKI) specifically targeting the ABL myristoyl pocket for CML, a form of cancer that begins in the bone marrow and leads to the growth of leukemic cells. TERN-601 is a small-molecule glucagon-like peptide-1 receptor (GLP-1R) agonist that is intended to be orally administered for obesity. TERN-501 is a thyroid hormone receptor beta (THR-b) agonist with high metabolic dysfunction-associated steatohepatitis (MASH). It is also focused on developing the TERN-800 series of small-molecule glucose-dependent insulinotropic polypeptide receptor (GIPR) modulators for obesity.
AI analysis of Terns Pharmaceuticals Inc (TERN)
holdTerns Pharmaceuticals Inc (TERN) is not a strong buy at the moment for a beginner, long-term investor with $50,000-$100,000 available for investment. The lack of significant positive catalysts, neutral trading sentiment, and limited financial growth trends suggest holding off on this stock for now.
Bewertungskennzahlen
The current forward P/E ratio for Terns Pharmaceuticals Inc (TERN) is 0.00, compared to its 5-year average forward P/E of -5.11.
Alphio AI Price Scenarios for TERN
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Whales holding TERN
Event-Zeitleiste
News
9.507-30stocktwitsViking Therapeutics Q2 Earnings Report Analysis
8.506-05stocktwitsPharmaceutical Giants Accelerate Acquisitions to Offset Patent Cliffs
6.005-28stocktwitsTruist Initiates Coverage on VKTX with Buy Rating and $83 Price Target
9.004-27NewsfilterTerns Receives FDA Breakthrough Therapy Designation for TERN-701
4.004-27moomooTERNS PHARMACEUTICALS INC.: OPPENHEIMER LOWERS RATING TO PERFORM FROM OUTPERFORM
TERN FAQ — answered by Alphio AI
Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Its product candidates in pipeline includes TERN-701, TERN-601 and TERN-501. TERN-701 is its oral, potent, allosteric BCR-ABL tyrosine kinase inhibitors (TKI) specifically targeting the ABL myristoyl pocket for CML, a form of cancer that begins in the bone marrow and leads to the growth of leukemic cells. TERN-601 is a small-molecule glucagon-like peptide-1 receptor (GLP-1R) agonist that is intended to be orally administered for obesity. TERN-501 is a thyroid hormone receptor beta (THR-b) agonist with high metabolic dysfunction-associated steatohepatitis (MASH). It is also focused on developing the TERN-800 series of small-molecule glucose-dependent insulinotropic polypeptide receptor (GIPR) modulators for obesity. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
Terns Pharmaceuticals Inc (TERN) is not a strong buy at the moment for a beginner, long-term investor with $50,000-$100,000 available for investment. The lack of significant positive catalysts, neutral trading sentiment, and limited financial growth trends suggest holding off on this stock for now.
Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.